EP4041722A4 - GPR119 AGONISTS - Google Patents
GPR119 AGONISTS Download PDFInfo
- Publication number
- EP4041722A4 EP4041722A4 EP20873622.3A EP20873622A EP4041722A4 EP 4041722 A4 EP4041722 A4 EP 4041722A4 EP 20873622 A EP20873622 A EP 20873622A EP 4041722 A4 EP4041722 A4 EP 4041722A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- gpr119 agonists
- gpr119
- agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940100607 GPR119 agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911833P | 2019-10-07 | 2019-10-07 | |
| PCT/US2020/054403 WO2021071837A1 (en) | 2019-10-07 | 2020-10-06 | Gpr119 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4041722A1 EP4041722A1 (en) | 2022-08-17 |
| EP4041722A4 true EP4041722A4 (en) | 2023-12-13 |
Family
ID=75436855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20873622.3A Withdrawn EP4041722A4 (en) | 2019-10-07 | 2020-10-06 | GPR119 AGONISTS |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11512065B2 (en) |
| EP (1) | EP4041722A4 (en) |
| JP (1) | JP2022552655A (en) |
| KR (1) | KR20220150270A (en) |
| CN (1) | CN114945560B (en) |
| AR (1) | AR120167A1 (en) |
| AU (1) | AU2020363377A1 (en) |
| BR (1) | BR112022006546A2 (en) |
| CA (1) | CA3156985A1 (en) |
| CL (1) | CL2022000856A1 (en) |
| IL (1) | IL291985A (en) |
| MX (1) | MX2022004142A (en) |
| PH (1) | PH12022550852A1 (en) |
| TW (1) | TW202128640A (en) |
| UY (1) | UY38908A (en) |
| WO (1) | WO2021071837A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220152164A1 (en) * | 2019-03-22 | 2022-05-19 | Kallyope, Inc. | Gpcr combination therapies |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| MX2021013662A (en) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE OF THESE. |
| IL325201A (en) | 2019-06-17 | 2026-02-01 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| JP2022552655A (en) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | GPR119 agonist |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic acetylcholine m1 receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | Gpr40 agonists |
| WO2023250323A1 (en) * | 2022-06-24 | 2023-12-28 | Kallyope, Inc. | Gpr119 and gpr40 agonist combination therapies for gut-brain axis disorders |
| CN116655598B (en) * | 2023-01-11 | 2025-04-25 | 黑龙江中医药大学 | Medicine for reducing blood sugar and preparation method thereof |
| CN117379409B (en) * | 2023-11-29 | 2025-10-31 | 郑州大学 | New application of oleoylethanolamide |
| WO2025137315A1 (en) * | 2023-12-22 | 2025-06-26 | Kallyope, Inc. | Combination therapy for treatment of metabolic disease |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010004347A1 (en) * | 2008-07-10 | 2010-01-14 | Prosidion Limited | Heterocyclic gpcr agonists |
| WO2013074388A1 (en) * | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
Family Cites Families (238)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| HUT71499A (en) | 1992-02-20 | 1995-11-28 | Black James Foundation | Bicyclo[2.2.2.]octane derivatives pharmaceutical compositions contg. the said compounds and process to prepare them |
| CA2158972A1 (en) | 1993-04-15 | 1994-10-27 | Harry Finch | 1,5-benzodiazepine derivatives having cck and/or gastrin antogonistic activity |
| CN1087725C (en) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | Enhancement of the effect of drugs by deuteration |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CZ286764B6 (en) | 1994-04-14 | 2000-06-14 | Glaxo Wellcome Inc | 5-Heterocyclo-1,5-benzodiazepine derivatives, process of their preparation and pharmaceutical preparation containing thereof |
| JPH09511998A (en) | 1994-04-15 | 1997-12-02 | グラクソ、ウェルカム、インコーポレーテッド | Method for inducing cholecystokinin agonist activity using 1,4-benzodiazepine compound |
| PE27497A1 (en) | 1994-04-15 | 1997-08-07 | Glaxo Inc | DERIVATIVES OF 1,5 BENZODIAZEPINA |
| FR2723739B1 (en) | 1994-08-19 | 1997-02-14 | Sanofi Sa | GLYCINAMIDE DERIVATIVES, METHODS FOR THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THEM. |
| GB9420747D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | 1,5 benzodiazepine derivatives |
| GB9420763D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Inc | Acetamide derivatives |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| DE60142885D1 (en) | 1996-04-12 | 2010-10-07 | Ontario Inc 1149336 | Glucagon-like peptide-2 |
| FR2763337B1 (en) | 1997-05-13 | 1999-08-20 | Sanofi Sa | NOVEL TRIAZOLE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| CO4970713A1 (en) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | DERIVATIVES OF CARBOXAMIDOTIAZOLES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
| AR022044A1 (en) | 1999-05-06 | 2002-09-04 | Glaxo Group Ltd | DERIVATIVES OF 1,5-BENZODIAZEPINA |
| KR20030042035A (en) | 2000-10-26 | 2003-05-27 | 사노피-신델라보 | Triazole derivatives and pharmaceutical compositions comprising them |
| HUP0004741A2 (en) | 2000-11-28 | 2002-12-28 | Sanofi-Synthelabo | Chemical process for the preparation of thiazole derivatives and a new intermediate |
| ATE396202T1 (en) | 2001-02-16 | 2008-06-15 | Conjuchem Biotechnologies Inc | LONG ACTING GLUCAGONE-LIKE PEPTIDE-2 FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS |
| EP1369698A1 (en) | 2002-06-07 | 2003-12-10 | Bayer Ag | Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5) |
| EP1558607B1 (en) * | 2002-10-30 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| WO2005035793A2 (en) | 2003-10-09 | 2005-04-21 | Decode Genetics Ehf. | Cckar markers and haplotypes associated with extreme weight conditions |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| JP4859665B2 (en) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | Alkoxyphenylpropanoic acid derivatives |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| JP2007284350A (en) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | Diabetes treatment |
| EP1843766A1 (en) | 2005-01-28 | 2007-10-17 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| CA2593858A1 (en) | 2005-01-31 | 2006-08-10 | Min Ge | Antidiabetic bicyclic compounds |
| US20060177438A1 (en) | 2005-02-08 | 2006-08-10 | New England Medical Center | Methods of altering absorption of hydrophobic compounds |
| DE602006020123D1 (en) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | GLUCAGON LIKE PEPTIDE-2 (GLP-2) ANALOG |
| EP1893603B1 (en) | 2005-06-02 | 2009-10-14 | F. Hoffmann-La Roche AG | Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists |
| WO2007067828A2 (en) | 2005-10-24 | 2007-06-14 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| WO2007088857A1 (en) | 2006-01-31 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Genetically modified animal and use thereof |
| AU2007238771B2 (en) | 2006-04-14 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
| WO2007120688A2 (en) | 2006-04-14 | 2007-10-25 | Merck & Co., Inc. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| ATE552245T1 (en) | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | ANTIDIABETIC BICYCLIC COMPOUNDS |
| WO2008028117A2 (en) | 2006-08-31 | 2008-03-06 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| WO2008063768A2 (en) | 2006-10-12 | 2008-05-29 | Case Western Reserve University | Compositions and methods for treating metabolic diseases |
| WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| US8039484B2 (en) | 2006-10-31 | 2011-10-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| AU2007319066B2 (en) | 2006-11-08 | 2013-09-19 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
| US7750048B2 (en) | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
| WO2008067222A1 (en) | 2006-11-28 | 2008-06-05 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| KR101555716B1 (en) | 2007-01-19 | 2015-09-25 | 인터셉트 파마슈티컬즈, 인크. | 5 23- 23-substituted bile acids as tgr5 modulators and methods of use thereof |
| ATE528006T1 (en) | 2007-01-26 | 2011-10-15 | Merck Sharp & Dohme | SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS |
| WO2008097976A1 (en) | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| US20090105124A1 (en) | 2007-08-23 | 2009-04-23 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
| JP2010539152A (en) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | Compounds for the treatment of metabolic disorders |
| RU2443699C2 (en) | 2007-09-20 | 2012-02-27 | Айрм Ллк | Compounds and compositions as gpr119 activity modulators |
| EP2203416B1 (en) | 2007-09-21 | 2016-10-26 | Sanofi | (carboxy alkylene-phenyl)-phenyl-oxalamides, method for their manufacture and their application as medicines |
| MX2010002419A (en) | 2007-09-21 | 2010-03-30 | Sanofi Aventis | (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament. |
| WO2009050309A1 (en) | 2007-10-17 | 2009-04-23 | Universidad De Cordoba | Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligonucleotide pairs for detection thereof by pcr |
| JP2011016722A (en) | 2007-10-23 | 2011-01-27 | Astellas Pharma Inc | Thiazolidinedione compound |
| RU2461551C2 (en) | 2007-10-24 | 2012-09-20 | Астеллас Фарма Инк. | Azolcarboxamide compound or its pharmaceutically acceptable salt |
| TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| US8299296B2 (en) | 2007-10-26 | 2012-10-30 | Japan Tobacco Inc. | Spiro compounds and pharmaceutical use thereof |
| CA2703217A1 (en) | 2007-10-29 | 2009-05-07 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2009106565A1 (en) * | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Agonists of gpr119 |
| JP5665160B2 (en) | 2008-03-26 | 2015-02-04 | パナソニックＩｐマネジメント株式会社 | Light emitting device and lighting apparatus |
| EA018703B1 (en) | 2008-04-07 | 2013-10-30 | Айрм Ллк | Compounds and compositions as modulators of gpr119 activity |
| AU2009269772A1 (en) * | 2008-07-10 | 2010-01-14 | Prosidion Limited | Piperidinyl GPCR agonists |
| WO2010014739A2 (en) | 2008-07-29 | 2010-02-04 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
| WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| WO2010016846A1 (en) | 2008-08-08 | 2010-02-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| US20110171164A1 (en) | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| JP5514831B2 (en) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | Substituted bicyclic amines for the treatment of diabetes |
| DK2698375T3 (en) | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
| ES2774368T3 (en) | 2008-11-19 | 2020-07-20 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods of using them |
| WO2010067233A1 (en) | 2008-12-08 | 2010-06-17 | Pfizer Inc. | 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir) |
| AU2010206789A1 (en) | 2009-01-23 | 2011-07-28 | Merck Sharp & Dohme Corp. | Bridged and fused antidiabetic compounds |
| WO2010085525A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused heterocyclic antidiabetic compounds |
| WO2010085522A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Pentafluorosulpholane-containing antidiabetic compounds |
| AR075051A1 (en) | 2009-02-05 | 2011-03-02 | Schering Corp | ANTIDIABETIC COMPOUNDS CONTAINING FTALAZINE |
| CN102395567A (en) | 2009-02-12 | 2012-03-28 | 埃克塞利希斯股份有限公司 | Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity |
| JP5657518B2 (en) | 2009-02-18 | 2015-01-21 | 武田薬品工業株式会社 | Fused heterocyclic compounds |
| JP2012136438A (en) | 2009-04-22 | 2012-07-19 | Astellas Pharma Inc | Tetrazole compound |
| EP2423176A4 (en) | 2009-04-22 | 2012-11-07 | Astellas Pharma Inc | Carboxylic acid compound |
| WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| AR078522A1 (en) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | SPIROPIPERIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES AND INTERMEDIARY COMPOUND FOR SYNTHESIS |
| EP2314616A1 (en) | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
| JPWO2011052756A1 (en) | 2009-10-30 | 2013-03-21 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisoxazole derivatives |
| AR078948A1 (en) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | SPYROPIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES |
| CN102781922A (en) | 2009-12-11 | 2012-11-14 | 埃克塞利希斯股份有限公司 | TGR5 agonists |
| NZ601408A (en) | 2009-12-25 | 2013-12-20 | Mochida Pharm Co Ltd | Novel 3-hydroxy-5-arylisothiazole derivative |
| CA2799414A1 (en) | 2010-05-18 | 2011-11-24 | Merck Sharp & Dohme Corp. | Spiro isoxazoline compounds as sstr5 antagonists |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| AU2011281134B2 (en) | 2010-07-23 | 2015-05-14 | Connexios Life Sciences Pvt. Ltd. | Agonists of GPR40 |
| US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| ES2555164T3 (en) | 2010-08-30 | 2015-12-29 | Nps Pharmaceuticals, Inc. | Synthesis of solid phase of h [Gly2] GLP-2 |
| JP5809157B2 (en) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | Cyclic amide derivative |
| JPWO2012070554A1 (en) | 2010-11-22 | 2014-05-19 | 国立大学法人京都大学 | peptide |
| AR084050A1 (en) | 2010-12-01 | 2013-04-17 | Boehringer Ingelheim Int | INDANILOXIDIHIDROBENZOFURANILACETIC ACIDS |
| WO2012082947A1 (en) | 2010-12-16 | 2012-06-21 | Irm Llc | Compounds and compositions as tgr5 agonists |
| WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
| CN103533951B (en) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15) |
| WO2012138845A1 (en) * | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| BR112013027883A2 (en) | 2011-04-27 | 2017-08-08 | Mochida Pharm Co Ltd | new 3-hydroxyisothiazole 1-oxide derivative |
| WO2012149236A1 (en) | 2011-04-28 | 2012-11-01 | Bristol-Myers Squibb Company | Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators |
| US9006228B2 (en) * | 2011-06-16 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| WO2013054338A1 (en) | 2011-07-06 | 2013-04-18 | Cadila Healthcare Limited | 2-thio-imidazole derivatives as tgr5 modulators |
| TWI537262B (en) | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | Novel 1,2,3,4-tetrahydroquinoline derivatives for the treatment of diabetes |
| EP2755675B1 (en) | 2011-09-12 | 2018-06-06 | Amunix Operating Inc. | Glucagon-like peptide-2 compositions and methods of making and using same |
| WO2013057743A1 (en) | 2011-10-21 | 2013-04-25 | Connexios Life Sciences Pvt. Ltd | Process for the preparation of an aryl oxime and salts thereof |
| JP2015506349A (en) | 2011-12-21 | 2015-03-02 | アルデリックス， インコーポレイテッド | Non-systemic TGR5 agonist |
| CN103429581B (en) | 2012-01-12 | 2015-08-26 | 江苏恒瑞医药股份有限公司 | Many lopps derivative, its preparation method and in application pharmaceutically |
| GB2498976A (en) * | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| US9382188B2 (en) | 2012-02-13 | 2016-07-05 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| US9181186B2 (en) | 2012-02-13 | 2015-11-10 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| NZ631569A (en) | 2012-02-28 | 2016-10-28 | Piramal Entpr Ltd | Phenyl alkanoic acid derivatives as gpr agonists |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| WO2013154163A1 (en) | 2012-04-11 | 2013-10-17 | 持田製薬株式会社 | Novel 5-aryl-1,2-thiazinane derivative |
| US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| AU2013255752B2 (en) | 2012-05-03 | 2017-11-09 | Zealand Pharma A/S | Glucagon-like-peptide-2 (GLP-2) analogues |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| WO2014019186A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US20150274664A1 (en) * | 2012-09-26 | 2015-10-01 | Marck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
| SG11201503247UA (en) | 2012-10-26 | 2015-06-29 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
| TWI692469B (en) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | GPR40 receptor agonist, method for manufacturing the agonist, and pharmaceutical composition containing the agonist as an active agent |
| AU2013352288B2 (en) | 2012-11-28 | 2017-11-23 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| PE20150968A1 (en) | 2012-11-28 | 2015-07-09 | Boehringer Ingelheim Int | NEW INDANILOXI DIHIDROBENZOFURANIL ACETIC ACIDS |
| JP6283862B2 (en) | 2012-12-07 | 2018-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | New indanyloxydihydrobenzofuranyl acetic acid |
| WO2014100025A1 (en) | 2012-12-17 | 2014-06-26 | Exelixis, Inc. | Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen |
| WO2014100021A1 (en) | 2012-12-17 | 2014-06-26 | Exelixis, Inc. | Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen |
| WO2014096440A2 (en) | 2012-12-21 | 2014-06-26 | Novozymes Biopharma Dk A/S | Composition |
| EP2953681B1 (en) | 2013-02-06 | 2017-03-15 | Boehringer Ingelheim International GmbH | New indanyloxydihydrobenzofuranylacetic acids |
| RU2015140066A (en) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC BICYCLIC COMPOUNDS |
| CN104059039B (en) | 2013-03-22 | 2017-03-15 | 正大天晴药业集团股份有限公司 | There is the fused ring compound of GPR40 function of receptors adjustment effects |
| CN104109115B (en) | 2013-04-16 | 2016-11-23 | 中国科学院上海药物研究所 | Phenylpropionic acid compound, its pharmaceutical composition, preparation method and the purposes of a kind of nitrogen heterocyclic ring link |
| AR096041A1 (en) | 2013-04-17 | 2015-12-02 | Piramal Entpr Ltd | CARBOXYLIC ACID DERIVATIVES RENT REPLACED AS RPG AGONISTS |
| WO2014187343A1 (en) | 2013-05-22 | 2014-11-27 | 四川海思科制药有限公司 | Benzofuran derivative, preparation method therefor, and medical application thereof |
| WO2014200349A1 (en) | 2013-06-13 | 2014-12-18 | Fast Forward Pharmaceutical B.V. | Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis. |
| WO2015000412A1 (en) | 2013-07-02 | 2015-01-08 | 四川海思科制药有限公司 | Benzocyclobutene derivative and preparation method and pharmaceutical application thereof |
| WO2015010655A1 (en) | 2013-07-26 | 2015-01-29 | 四川海思科制药有限公司 | Triadic fused cyclic carboxylic acids derivatives, preparation method therefor and pharmaceutical use thereof |
| TWI648401B (en) | 2013-07-31 | 2019-01-21 | 安美基公司 | Growth Differentiation Factor 15 (GDF-15) Construct |
| PT3031799T (en) | 2013-08-09 | 2018-07-04 | Takeda Pharmaceuticals Co | AROMATIC COMPOUND |
| CN104418801B (en) | 2013-08-19 | 2016-10-05 | 上海润诺生物科技有限公司 | Benzo piperidine ring and benzo morpholine cyclics, its preparation method and medical applications |
| CN105473595A (en) | 2013-08-23 | 2016-04-06 | 福建海西新药创制有限公司 | Carboxylic acid compounds in treatment of diabetes mellitus |
| WO2015028960A1 (en) | 2013-08-28 | 2015-03-05 | Piramal Enterprises Limited | Substituted heterocyclic derivatives as gpr agonists and uses thereof |
| WO2015032328A1 (en) | 2013-09-03 | 2015-03-12 | 四川海思科制药有限公司 | Indane derivative, preparation method therefor, and pharmaceutical application thereof |
| WO2015044073A1 (en) | 2013-09-26 | 2015-04-02 | Boehringer Ingelheim International Gmbh | Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists |
| JO3442B1 (en) | 2013-10-07 | 2019-10-20 | Takeda Pharmaceuticals Co | Antagonists of somatostatin receptor subtype 5 (sstr5) |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2015062486A1 (en) | 2013-10-31 | 2015-05-07 | Sunshine Lake Pharma Co., Ltd. | Biphenyl compounds and uses thereof |
| IN2013MU03577A (en) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
| ES2747973T3 (en) | 2013-11-15 | 2020-03-12 | Merck Sharp & Dohme | Anti-diabetic tricyclic compounds |
| WO2015078802A1 (en) | 2013-11-28 | 2015-06-04 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarboxylic acids |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| TW201609722A (en) | 2013-12-13 | 2016-03-16 | 美國禮來大藥廠 | A novel triazolo-pyridine compound |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| KR20160095117A (en) | 2014-01-10 | 2016-08-10 | 일라이 릴리 앤드 캄파니 | Phenyl-triazolo-pyridine compounds |
| US9809592B2 (en) | 2014-01-10 | 2017-11-07 | Eli Lilly And Company | Isopropyl triazolo pyridine compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2015160772A1 (en) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Tetrahydro-benzoimidazolyl modulators of tgr5 |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
| SMT202000070T1 (en) | 2014-05-29 | 2020-03-13 | Bar Pharmaceuticals S R L | Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| EP3164538A1 (en) | 2014-07-02 | 2017-05-10 | Arçelik Anonim Sirketi | Built-in household appliance unpowered control and status indication device |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US10968193B2 (en) | 2014-08-08 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2016032120A1 (en) | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | Novel amino-phenyl-sulfonyl-acetate derivative and use thereof |
| WO2016054208A1 (en) | 2014-10-03 | 2016-04-07 | Mayo Foundation For Medical Education And Research | Targeting tgr5 to treat disease |
| TW201629033A (en) | 2014-10-08 | 2016-08-16 | 健生藥品公司 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
| KR101726819B1 (en) * | 2014-10-27 | 2017-04-13 | 동아에스티 주식회사 | Compound having agonistic activity to gpr119, method for preparation thereof and pharmaceutical compositon comprising the same |
| US20180280480A1 (en) | 2014-10-31 | 2018-10-04 | Gubra Aps | Compositions and peptides having dual glp-1r and glp-2r agonist activity |
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| EP3256134A4 (en) | 2015-02-11 | 2018-10-03 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2016161003A1 (en) | 2015-03-31 | 2016-10-06 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| TW201712012A (en) | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives |
| JP6861703B2 (en) | 2015-06-19 | 2021-04-21 | インターセプト ファーマシューティカルズ， インコーポレイテッド | TGR5 modifier and how to use it |
| JP6772133B2 (en) | 2015-07-02 | 2020-10-21 | サントリーホールディングス株式会社 | GLP-2 secretagogue composition |
| TW201716432A (en) | 2015-07-06 | 2017-05-16 | 諾佛 儂迪克股份有限公司 | Novel peptides and peptide derivatives and uses thereof |
| EP3331860B1 (en) | 2015-08-07 | 2019-07-17 | Boehringer Ingelheim International GmbH | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10604544B2 (en) | 2015-08-07 | 2020-03-31 | Intercept Pharmaceuticals, Inc. | Methods for preparation of bile acids and derivatives thereof |
| WO2017027312A1 (en) | 2015-08-12 | 2017-02-16 | Janssen Pharmaceutica Nv | Gpr40 agonists for the treatment of type ii diabetes |
| US9908873B2 (en) | 2015-08-12 | 2018-03-06 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| US9920040B2 (en) | 2015-08-12 | 2018-03-20 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| US20180354962A1 (en) | 2015-09-09 | 2018-12-13 | Boehringer Ingelheim International Gmbh | [{[2,3-Dihydro-1H-inden-1-yl]amino}-2H,3H-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof |
| AU2016325619A1 (en) | 2015-09-24 | 2018-04-12 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation bile acid derivatives |
| AU2016350690C1 (en) | 2015-11-06 | 2020-04-23 | Intercept Pharmaceuticals, Inc. | Methods for the preparation of obeticholic acid and derivatives thereof |
| TWI773657B (en) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN108697795A (en) | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral receptor therapies |
| WO2017172505A1 (en) | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10106553B2 (en) | 2016-04-11 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
| WO2017180577A1 (en) | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating cancer |
| WO2018005801A2 (en) | 2016-07-01 | 2018-01-04 | Venenum Biodesign Llc | Novel non-systemic tgr5 agonists |
| US10654834B2 (en) | 2016-07-01 | 2020-05-19 | Venenum Biodesign, LLC | Non-systemic TGR5 agonists |
| WO2018009778A1 (en) | 2016-07-07 | 2018-01-11 | Baylor College Of Medicine | Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes |
| KR20190057108A (en) | 2016-09-30 | 2019-05-27 | 인터셉트 파마슈티컬즈, 인크. | Crystalline form of bile acid derivatives |
| EP3526346A1 (en) | 2016-10-12 | 2019-08-21 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
| WO2018081047A1 (en) | 2016-10-25 | 2018-05-03 | Janssen Pharmaceutica Nv | Cyclohexyl gpr40 agonists for the treatment of type ii diabetes |
| CN110088089B (en) | 2016-10-25 | 2023-08-29 | 勃林格殷格翰国际有限公司 | Benzyl amino pyridyl cyclopropane carboxylic acid, pharmaceutical composition and application thereof |
| US10125101B2 (en) | 2016-11-28 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018103868A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| WO2018104558A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| JP2020500890A (en) | 2016-12-09 | 2020-01-16 | ジーランド・ファーマ・ア／エス | GLP-1 / GLP-2 dual agonist |
| AU2017371516C1 (en) | 2016-12-09 | 2021-09-02 | Zealand Pharma A/S | Acylated GLP-1/GLP-2 dual agonists |
| WO2018104559A1 (en) | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| KR102007633B1 (en) | 2016-12-15 | 2019-08-06 | 일동제약(주) | Novel phenyl propionic acid derivatives and uses thereof |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| EP3573959B1 (en) | 2017-01-26 | 2021-07-28 | Boehringer Ingelheim International GmbH | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| CN110214135B (en) | 2017-01-26 | 2023-02-21 | 勃林格殷格翰国际有限公司 | Indanyl amino pyrazinyl cyclopropane carboxylic acid, pharmaceutical composition and application thereof |
| CN110177773B (en) | 2017-01-26 | 2023-08-25 | 勃林格殷格翰国际有限公司 | Benzylaminopyridylcyclopropanecarboxylic acid, its pharmaceutical composition and its use |
| JP7050792B2 (en) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzyloxypyrazinylcyclopropanecarboxylic acid, its pharmaceutical composition and use |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| WO2018142363A1 (en) | 2017-02-06 | 2018-08-09 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use compositions of glp-2 analogues through self-administrable devices |
| US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
| GB201704714D0 (en) | 2017-03-24 | 2017-05-10 | Caldan Therapeutics Ltd | Pharmaceutical compounds |
| AR111199A1 (en) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | GPR40 AGONIST AROMATIC COMPOUND |
| JPWO2018181847A1 (en) | 2017-03-31 | 2020-03-05 | 武田薬品工業株式会社 | Aromatic compounds |
| CN107162921B (en) | 2017-05-27 | 2019-12-13 | 中国药科大学 | A kind of phenoxyacetic acid derivative, its preparation method and its use as medicine |
| WO2018222701A1 (en) | 2017-05-30 | 2018-12-06 | Intercept Pharmaceuticals, Inc. | Treatment of renal diseases with a bile acid derivative |
| WO2018226724A1 (en) | 2017-06-05 | 2018-12-13 | Intercept Pharmaceuticals, Inc. | Treatment and prevention of diabetic eye diseases with a bile acid derivatives |
| BR112019026711A2 (en) | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | dosage regimens for the administration of glucagon-2-like peptide analogs (glp-2) |
| BR112019027458A2 (en) | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | methods and intermediates for the preparation of bile acid derivatives |
| US20200199192A1 (en) | 2017-08-22 | 2020-06-25 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| WO2019086559A1 (en) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprising a glp-2 receptor agonist and a co-polyamino acid carrying carboxylate charges and hydrophobic radicals |
| US11660328B2 (en) | 2017-11-06 | 2023-05-30 | Takeda Pharmaceutical Company Limited | GLP-2 analogs and peptibodies for administration before, during or after surgery |
| EP3709995A4 (en) | 2017-11-16 | 2021-04-14 | Merck Sharp & Dohme Corp. | ANTIDIABETIC BICYCLIC COMPOUNDS |
| US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| US20220152164A1 (en) | 2019-03-22 | 2022-05-19 | Kallyope, Inc. | Gpcr combination therapies |
| WO2020242943A1 (en) | 2019-05-29 | 2020-12-03 | Kallyope, Inc. | Gpr40 agonists |
| JP2022552655A (en) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | GPR119 agonist |
| WO2021113363A1 (en) | 2019-12-03 | 2021-06-10 | Kallyope, Inc. | Sstr5 antagonists |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | Gpr40 agonists |
| AU2021225966A1 (en) | 2020-02-28 | 2022-09-15 | Kallyope, Inc. | GPR40 agonists |
-
2020
- 2020-10-06 JP JP2022520753A patent/JP2022552655A/en active Pending
- 2020-10-06 WO PCT/US2020/054403 patent/WO2021071837A1/en not_active Ceased
- 2020-10-06 KR KR1020227015272A patent/KR20220150270A/en not_active Ceased
- 2020-10-06 PH PH1/2022/550852A patent/PH12022550852A1/en unknown
- 2020-10-06 EP EP20873622.3A patent/EP4041722A4/en not_active Withdrawn
- 2020-10-06 MX MX2022004142A patent/MX2022004142A/en unknown
- 2020-10-06 AU AU2020363377A patent/AU2020363377A1/en not_active Abandoned
- 2020-10-06 IL IL291985A patent/IL291985A/en unknown
- 2020-10-06 CN CN202080085027.9A patent/CN114945560B/en active Active
- 2020-10-06 BR BR112022006546A patent/BR112022006546A2/en unknown
- 2020-10-06 CA CA3156985A patent/CA3156985A1/en active Pending
- 2020-10-07 AR ARP200102771A patent/AR120167A1/en not_active Application Discontinuation
- 2020-10-07 UY UY0001038908A patent/UY38908A/en not_active Application Discontinuation
- 2020-10-07 TW TW109134713A patent/TW202128640A/en unknown
-
2022
- 2022-02-03 US US17/592,348 patent/US11512065B2/en active Active
- 2022-04-05 CL CL2022000856A patent/CL2022000856A1/en unknown
- 2022-07-28 US US17/875,776 patent/US20230061736A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010004347A1 (en) * | 2008-07-10 | 2010-01-14 | Prosidion Limited | Heterocyclic gpcr agonists |
| WO2013074388A1 (en) * | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2021071837A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114945560B (en) | 2024-08-13 |
| JP2022552655A (en) | 2022-12-19 |
| CL2022000856A1 (en) | 2022-11-25 |
| PH12022550852A1 (en) | 2023-05-03 |
| UY38908A (en) | 2021-04-30 |
| US20230061736A1 (en) | 2023-03-02 |
| IL291985A (en) | 2022-06-01 |
| KR20220150270A (en) | 2022-11-10 |
| AR120167A1 (en) | 2022-02-02 |
| EP4041722A1 (en) | 2022-08-17 |
| US11512065B2 (en) | 2022-11-29 |
| US20220153719A1 (en) | 2022-05-19 |
| TW202128640A (en) | 2021-08-01 |
| AU2020363377A1 (en) | 2022-04-21 |
| CN114945560A (en) | 2022-08-26 |
| WO2021071837A1 (en) | 2021-04-15 |
| MX2022004142A (en) | 2022-09-21 |
| BR112022006546A2 (en) | 2022-08-30 |
| CA3156985A1 (en) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4041722A4 (en) | GPR119 AGONISTS | |
| EP4069686C0 (en) | GPP-1 receptor agonists | |
| IL280290A (en) | IL2 agonists | |
| EP4007752C0 (en) | KIF18A INHIBITORS | |
| MA54543A (en) | KIF18A INHIBITORS | |
| MA54550A (en) | KIF18A INHIBITORS | |
| EP4007753C0 (en) | KIF18A INHIBITORS | |
| DK3762380T3 (en) | PHENYLPYRROLIDINONE FORMYLPEPTIDE-2 RECEPTOR AGONISTS | |
| EP4051676A4 (en) | BCL-2 INHIBITORS | |
| MA52812A (en) | SARM1 INHIBITORS | |
| MA52813A (en) | SARM1 INHIBITORS | |
| EP3747920A4 (en) | BLOCK COPOLYMER COMPOSITION | |
| IL292101A (en) | holder | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| EP3801499A4 (en) | MRSA1 INHIBITORS | |
| EP3980011C0 (en) | SARM1 INHIBITORS | |
| EP4036334A4 (en) | DETERMINATION DEVICE | |
| DK3930878T3 (en) | CROSS-FILTERING DEVICE | |
| EP3751679A4 (en) | CONNECTOR HOLDING MECHANISM | |
| IL312125A (en) | RXFP1 agonists | |
| MA51611A (en) | PI4KIIIBETA INHIBITORS | |
| EP3751266A4 (en) | SPECIMEN | |
| EP4022337C0 (en) | POSITION DETERMINATION | |
| IL288536A (en) | il2 agonists | |
| PT3801538T (en) | TLR7 AGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220401 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230521 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/506 20060101ALI20230807BHEP Ipc: A61P 3/00 20060101ALI20230807BHEP Ipc: C07H 15/26 20060101ALI20230807BHEP Ipc: C07D 405/14 20060101ALI20230807BHEP Ipc: C07D 403/14 20060101ALI20230807BHEP Ipc: C07D 401/14 20060101ALI20230807BHEP Ipc: C07D 401/12 20060101ALI20230807BHEP Ipc: C07D 401/04 20060101AFI20230807BHEP |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20231114 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/506 20060101ALI20231108BHEP Ipc: A61P 3/00 20060101ALI20231108BHEP Ipc: C07H 15/26 20060101ALI20231108BHEP Ipc: C07D 405/14 20060101ALI20231108BHEP Ipc: C07D 403/14 20060101ALI20231108BHEP Ipc: C07D 401/14 20060101ALI20231108BHEP Ipc: C07D 401/12 20060101ALI20231108BHEP Ipc: C07D 401/04 20060101AFI20231108BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20250128 |